Dako Archives - Meximp Technologies

Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma

Approval expands PD-L1 testing onto an automated workflow to support treatment decisions with KEYTRUDA®...

Test enables identification of patients whose tumors express PD-L1 for potential treatment with KEYTRUDA®...

Agilent to Acquire Biocare Medical, a Global Leader in Clinical and Research Pathology Solutions SANTA CLARA, Calif,...

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung...

How Agilent is Driving Advanced Cancer Diagnostics For a quarter of a century, World Cancer Day (February 4th) has...

Agilent Companion Diagnostic Assay PD-L1 IHC 28-8 pharmDx Receives European IVDR Certification SANTA CLARA, Calif.,...

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Gastric or Gastroesophageal Junction (GEJ)...